Dr. Khawaja Muhammad Muddassir, MD

Dr. Muddassir practices at Saint Francis Hospital-Memphis in Memphis, Tennessee, part of Tenet Healthcare.

Dr. Muddassir's NPI, 1003043043, was assigned on June 17, 2009. Dr. Muddassir holds Tennessee license 52180.

Dr. Muddassir's primary practice is Saint Francis Hospital-Memphis, at 5959 Park Ave, Memphis, TN 38119 in Shelby County. The practice phone is (901) 765-1000.

Dr. Muddassir's primary practice is Saint Francis Hospital-Memphis in Memphis, Tennessee, part of Tenet Healthcare. Dr. Muddassir is also affiliated with Methodist University Hospital. The medical group on file is Tri-State Neurology. Dmand AI also links Dr. Muddassir to 4 more hospitals, 3 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Muddassir practices, 8 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Muddassir's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Muddassir is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Muddassir's licenses on file in 2 states: Tennessee and California.

CMS data shows 1,486 Medicare services from Dr. Muddassir across 8 procedure codes in 2024, for 191 Medicare patients. Medicare paid $120,022 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 191 Medicare patients who saw Dr. Muddassir in 2024. The largest group is 65 to 74, with 68 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 32% are also on Medicaid. Their average risk score is 3.42, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Muddassir's median patient age at 61, with 43% women.

In 2024, Dr. Muddassir wrote 86 Medicare Part D claims for 15 patients. 90% of them were for generic drugs. They cover 6 drugs, with $1,379,617 in total drug cost. In 2020, CMS named 255 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 96 out of 100 for Dr. Muddassir for performance year 2024, reported through an alternative payment model (APM). Dr. Muddassir accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 9 papers to Dr. Muddassir, published from 2020 to 2023. 2021 was the busiest year, with 3. The most frequent topics are Trace Elements, Cadmium and Colorectal Neoplasms. Dr. Muddassir's most frequent co-authors are Chinelo Ngozi Animalu, MD, Anirudh Aron, MD and Ali Azim, MD.

Dmand AI links Dr. Muddassir to 10 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Adenocarcinoma of Lung, Biliary Atresia and Low Back Pain.

CMS Open Payments shows 26 general payments to Dr. Muddassir from 10 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 47% of the total. Intuitive Surgical, Inc. paid the most, $3,463.